Event Ends
SPEAKERS
Prof. Dr. dr. Sidartawan Soegondo, Sp.PD-KEMD, FACE
dr. Rochsismandoko, SpPD-KEMD, FINASIM, FACE
Prof. Dr. dr. Askandar Tjokroprawiro, SpPD-KEMD, FINASIM
Prof. Dr. dr. Pradana Soewondo, SpPD-KEMD
Prof. Dr. dr. Karel Pandelaki, SpPD-KEMD
Dr. Katsuhito Mori, PhD
Prof. Dr. dr. Eva Decroli, SpPD-KEMD
Prof. Dr. dr. H. Imam Subekti, SpPD-KEMD
Prof. Dr. dr. Ketut Suastika, SpPD-KEMD, FINASIM
Drs. Andi Wijaya
Prof. Dr. dr. Achmad Rudijanto, SpPD-KEMD
Dr. Banshi Saboo
3 days
12 speakers
12 moderators
13 sessions
20 topics
3 days
12 speakers
12 moderators
13 sessions
20 topics
SCHEDULE
13:15-13:45
New Aproach of Combination Therapy in Diabetes Management ?
14.00-14.30
New Paradigm in T2DM Management (Recent Advances of Long Acting GLP - 1RA with CVD Benefits as Considered in Guidelines - 2020).
14.30-15.00
New Perspective on Recent CVOT swith Glucose - Lowering Therapies
15.00-15.30
CVD in Diabetes: Going beyond Glucose Control
15.45-16.15
Tailoring Treatment Options Based on Diabetes Comorbidities
16.15-16.45
The Role of 2nd Generation Basal Insulin Analogs in Personalizing Diabetes management and Patient Case Sharing
08.00 - 09.00
Modern SU in Clinical Practice : History and Reality
09.00 - 09.30
Significance of Measuring GA for Diabet Complication Patients
09.45 - 10.15
Addressing the Unmet needs unManaging the Broad Range of T2DM Patients : is it Possible ?
10.15 - 10.45
Powerful Strategy to Overcome the Challenge in T2DM Management for Elderly : Case Study Approach
11.00 - 11.30
Identying the need for intensification of therapy in T2D : Why do patient fail to reach glycemic target
11.30-12.00
Getting to Goal : Evidence of Fix Ratio Combination Basal insulin/GLP1RA
12.00-12.30
T2DM Patient profile benefit of Fix Ratio Combination (Insulin Glargine/Lixisenetide): Learning from clinical studies.
14:00-15:00
The Debut of New Way in Insulin Treatment
08.00 - 08.45
The Many Secret Lives of Adipocytes Implication for Cardiometabolic Diseases
08.45 - 09.15
A New Paradigmin T2D Management from Metabolic to Cardiorenal Protection,What Guidelines have told us
09.30 - 10.00
Prediabetes Management : Learning from Diabetes Program and Guidelines
10.00 - 10.30
Optimization of FDC Metformin - Glibenclamide in T2DM Treatment
10.45 - 11.15
How Do GLP-1 RA and SGLT-2i ProvideCardiorenal Benefits in Patients with T2D?
11.15 - 11.45
Fresh from ADA 2020 : Recent Guideline on Management ofT2D Patients with High CV Risk
- Friday
04 September 2020 13:15-13:45
New Aproach of Combination Therapy in Diabetes Management ?
Sidartawan Soegondo (Jakarta)14.00-14.30
New Paradigm in T2DM Management (Recent Advances of Long Acting GLP - 1RA with CVD Benefits as Considered in Guidelines - 2020).
Askandar Tjokroprawiro (Surabaya)14.30-15.00
New Perspective on Recent CVOT swith Glucose - Lowering Therapies
Pradana Soewondo (Jakarta)15.00-15.30
CVD in Diabetes: Going beyond Glucose Control
Sidartawan Soegondo (Jakarta)15.45-16.15
Tailoring Treatment Options Based on Diabetes Comorbidities
Sidartawan Soegondo (Jakarta)16.15-16.45
The Role of 2nd Generation Basal Insulin Analogs in Personalizing Diabetes management and Patient Case Sharing
Karel Pandelaki (Manado)- Saturday
05 September 2020 08.00 - 09.00
Modern SU in Clinical Practice : History and Reality
Sidartawan Soegondo (Jakarta)09.00 - 09.30
Significance of Measuring GA for Diabet Complication Patients
Katsuhito Mori (Jepang)09.45 - 10.15
Addressing the Unmet needs unManaging the Broad Range of T2DM Patients : is it Possible ?
Sidartawan Soegondo(Jakarta)10.15 - 10.45
Powerful Strategy to Overcome the Challenge in T2DM Management for Elderly : Case Study Approach
Eva Decroli(Padang)11.00 - 11.30
Identying the need for intensification of therapy in T2D : Why do patient fail to reach glycemic target
Ketut Suastika (Bali)11.30-12.00
Getting to Goal : Evidence of Fix Ratio Combination Basal insulin/GLP1RA
Imam Subekti (Jakarta)12.00-12.30
T2DM Patient profile benefit of Fix Ratio Combination (Insulin Glargine/Lixisenetide): Learning from clinical studies.
Sidartawan Soegondo (Jakarta)14:00-15:00
The Debut of New Way in Insulin Treatment
Sidartawan Soegondo (Jakarta)- Sunday
06 September 2020 08.00 - 08.45
The Many Secret Lives of Adipocytes Implication for Cardiometabolic Diseases
Andi Wijaya(Jakarta)08.45 - 09.15
A New Paradigmin T2D Management from Metabolic to Cardiorenal Protection,What Guidelines have told us
Sidartawan Soegondo(Jakarta)09.30 - 10.00
Prediabetes Management : Learning from Diabetes Program and Guidelines
Sidartawan Soegondo(Jakarta)10.00 - 10.30
Optimization of FDC Metformin - Glibenclamide in T2DM Treatment
Achmad Rudijanto(Malang)10.45 - 11.15
How Do GLP-1 RA and SGLT-2i ProvideCardiorenal Benefits in Patients with T2D?
Sidartawan Soegondo(Jakarta)11.15 - 11.45
Fresh from ADA 2020 : Recent Guideline on Management ofT2D Patients with High CV Risk
Banshi Shaboo(India)
FRIDAY, 04 SEPTEMBER 2020
13:15-13:45
New Aproach of Combination Therapy in Diabetes Management ?
14.00-14.30
New Paradigm in T2DM Management (Recent Advances of Long Acting GLP - 1RA with CVD Benefits as Considered in Guidelines - 2020).
14.30-15.00
New Perspective on Recent CVOT swith Glucose - Lowering Therapies
15.00-15.30
CVD in Diabetes: Going beyond Glucose Control
15.45-16.15
Tailoring Treatment Options Based on Diabetes Comorbidities
16.15-16.45
The Role of 2nd Generation Basal Insulin Analogs in Personalizing Diabetes management and Patient Case Sharing
SATURDAY, 05 SEPTEMBER 2020
08.00 - 09.00
Modern SU in Clinical Practice : History and Reality
09.00 - 09.30
Significance of Measuring GA for Diabet Complication Patients
09.45 - 10.15
Addressing the Unmet needs unManaging the Broad Range of T2DM Patients : is it Possible ?
10.15 - 10.45
Powerful Strategy to Overcome the Challenge in T2DM Management for Elderly : Case Study Approach
11.00 - 11.30
Identying the need for intensification of therapy in T2D : Why do patient fail to reach glycemic target
11.30 - 12.00
Getting to Goal : Evidence of Fix Ratio Combination Basal insulin/GLP1RA
12.00-12.30
T2DM Patient profile benefit of Fix Ratio Combination (Insulin Glargine/Lixisenetide): Learning from clinical studies.
14:00-15:00
The Debut of New Way in Insulin Treatment.
SUNDAY, 06 SEPTEMBER 2020
08.00 - 08.45
The Many Secret Lives of Adipocytes Implication for Cardiometabolic Diseases
08.45 - 09.15
A New Paradigmin T2D Management from Metabolic to Cardiorenal Protection,What Guidelines have told us
09.30 - 10.00
Prediabetes Management : Learning from Diabetes Program and Guidelines
10.00 - 10.30
Optimization of FDC Metformin - Glibenclamide in T2DM Treatment
10.45 - 11.15
How Do GLP-1 RA and SGLT-2i ProvideCardiorenal Benefits in Patients with T2D?
11.15 - 11.45
Fresh from ADA 2020 : Recent Guideline on Management ofT2D Patients with High CV Risk
2019
SUPPORTED BY
